Shengkai Xia et al. [6] revealed that mesothelin plays a critical role in BMs in non-small cell lung cancer (NSCLC) via the JNK/MET signaling pathway, highlighting it as a potential therapeutic target for preventing brain metastasis in NSCLC patients. Here, MET is linked to non-small cell lung carcinoma.